A Phase I/II Study of Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 03 Dec 2018
At a glance
- Drugs Carfilzomib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 26 Nov 2018 Status changed from active, no longer recruiting to discontinued.
- 19 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 19 Jul 2017 Status changed from recruiting to active, no longer recruiting.